1. [Recurrent invasive pneumococcal disease in a patient with IgG-κ smoldering multiple myeloma].
- Author
-
Chiba M, Oshimi K, Matsukawa T, Okada K, and Miyagishima T
- Subjects
- Aged, Female, Humans, Pneumococcal Infections drug therapy, Pneumococcal Infections immunology, Pneumococcal Vaccines therapeutic use, Recurrence, Smoldering Multiple Myeloma immunology, Vaccines, Conjugate therapeutic use, Immunoglobulins, Intravenous therapeutic use, Pneumococcal Infections complications, Smoldering Multiple Myeloma complications
- Abstract
A 68-year-old female with smoldering multiple myeloma (IgG-κ type) was admitted to the hospital owing to general fatigue, fever, and pain in the right leg. On the day following admission, she developed shock, and a blood culture revealed Streptococcus pneumoniae. She was diagnosed with septic shock and invasive pneumococcal disease (IPD). She received antibiotics and intravenous immunoglobulin and improved after several days. She had a history of recurrent IPD and had received the pneumococcal polysaccharide vaccine 23 (PPSV23) 2 years earlier. Therefore, we inquired with the National Institute of Infectious Diseases if the pneumococcal serotype isolated from her present IPD contained PPSV23. The results showed that her serotype was 19F, a serotype present in PPSV23. We administered pneumococcal conjugate vaccine 13 (PCV13) ; however, she was unable to mount high enough opsonophagocytic assay titers against some serotypes, including 19F. We think she was unable to mount effective humoral immune responses to PPSV23 or PCV13 owing to her underlying disease, smoldering myeloma. It should be considered how IPD can be effectively prevented in patients with multiple myeloma.
- Published
- 2018
- Full Text
- View/download PDF